FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified autologous ...

NOVEMBER 12, 2024

Blincyto Approved as Consolidation for CD19-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL

The FDA has approved blinatumomab (Blincyto, Amgen) for adult and pediatric patients aged 1 month and older with ...

JUNE 17, 2024

FDA Grants Accelerated Approval to Iclusig With Chemotherapy for Newly Diagnosed Ph-positive ALL

The FDA granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A.) with chemotherapy for ...

MARCH 19, 2024

Besponsa Approved for Pediatric Patients With Acute Lymphoblastic Leukemia

The FDA approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients aged 1 year and older with ...

MARCH 7, 2024

Obesity Plays Adverse Role in AYAs’ Response to ALL Treatment Regimens

Among adolescents and young adults (AYAs) being treated for acute lymphoblastic leukemia (ALL), those who are ...

AUGUST 31, 2023

In Newly Diagnosed ALL, Addition of BiTE to Consolidation Therapy Improves OS

The addition of the bispecific T-cell engager blinatumomab (Blincyto, Amgen) to the consolidation regimen of ...

JANUARY 7, 2023

BiTE Therapy Shows Promise in R/R ALL

Although only a phase 1b dose-finding study in patients with relapsed/refractory (R/R) B-cell precursor acute ...

MARCH 16, 2022

Managing Asparaginase Hypersensitivity Reactions

Asparaginase-based regimens are gaining a foothold in the treatment of acute lymphoblastic leukemia and ...

MARCH 7, 2022

Studies Point to Optimal Dosing in Acute Leukemia and Lymphoma

Two new studies of drugs already licensed for cancer—one indicated for acute lymphoblastic leukemia and one ...

JANUARY 20, 2022

FDA Approves Longer-Acting Calaspargase Pegol-mknl for ALL

The FDA approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC) as part of a multi-agent ...

JANUARY 2, 2019

CAR T-Cell Therapy Roundup

The field of CAR therapy has been heating up, with the recent approval of Novartis’ tisagenlecleucel ...

SEPTEMBER 21, 2017

Reducing Infection Risk in Young Leukemia Patients

The first few weeks is a crucial stage in monitoring and preventing infection in these children.

SEPTEMBER 18, 2017